Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT1071250076) titled 'Observational study of treatment persistence of acalabrutinib-obinutuzumab combination therapy or acalabrutinib monotherapy in treatment-naive B-chronic lymphocytic leukemia (B-CLL) patients' on Sept. 30.
Study Type: Observational
Primary Sponsor: Shibayama Hirohiko
Condition:
B-cell chronic lymphocytic leukemia
Chronic lymphocytic leukemia, B-cell chronic lymphocytic leukemia, B-CLL
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 01/10/2025
Target Sample Size: 65
To know more, visit https://jrct.mhlw.go.jp/latest-detail/jRCT1071250076
Published by HT Digital Content Services ...